Segmented Synthetic Tumor-Targeting Compounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer therapies, such as immunotoxins, face challenges including unspecific toxicity, low efficacy, and high manufacturing costs, necessitating the development of compounds that are specific to tumor cells and can be synthesized at lower costs.
Innovation Solution
Development of novel synthetic compounds with a backbone structure resembling immunoglobulins, comprising effector functions, flexible linker structures, and coupling sites for binders that target tumor cell markers, utilizing synthetic binders and effectors to activate pathogen pattern recognition receptors, thereby enhancing immune response specificity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotoxins are used to target cancer cells, then tumor cell targeting capability is improved, but unspecific toxicity increases
Solution Approach 1:
The compound is divided into separate functional modules: a backbone structure containing effector functions and separate binder moieties that specifically bind to tumor markers. This segmentation allows the effector to remain sequestered until specific binding occurs at the tumor site, reducing unspecific toxicity while maintaining targeting capability.
Solution Approach 2:
The backbone structure acts as an intermediary carrier that transports the effector function to the tumor site through specific binding to tumor markers. This intermediary approach ensures that the toxic effector is delivered specifically to tumor cells rather than being distributed systemically, thereby reducing unsspecific toxicity.
2Reliability
If conventional immunotoxins are used, then tumor targeting is achieved, but manufacturing cost increases
Solution Approach 1:
The invention uses synthetic peptide binders that replicate the tumor-targeting function of complex natural antibodies but can be produced through simpler chemical synthesis. These synthetic copies maintain the essential binding functionality while eliminating the need for complex biologics manufacturing processes.
Solution Approach 2:
The compound employs synthetic peptide binders and chemically synthesized backbone structures that are more economical to produce than natural immunotoxins. These synthetic components can be manufactured through standardized chemical processes, significantly reducing production costs while maintaining therapeutic functionality.
3Reliability
If complex immunotoxin conjugates are used, then tumor cell binding is improved, but device complexity increases
Solution Approach 1:
The compound structure is segmented into a standardized backbone and interchangeable binder modules. This modular segmentation simplifies the overall design by allowing systematic assembly of functional components rather than creating complex unique conjugates for each application.
Solution Approach 2:
The backbone structure serves multiple functions: it provides structural stability, contains the effector function, and offers attachment points for various binder types. This multi-functionality reduces the need for separate complex structures for each function, thereby reducing overall compound complexity while maintaining effective tumor cell binding.
Data Source
AI summary
The invention relates to a novel compounds targeting human cancer cells, a method for synthesis of such compounds, and use of such compounds in treating cancer.